Drug Profile

Morphine/pramipexole - Amalgent Therapeutics

Alternative Names: AMGT-0220

Latest Information Update: 04 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amalgent Therapeutics
Class Antidepressants; Antiparkinsonians; Benzothiazoles; Morphinans; Opioid analgesics; Small molecules
Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Pain

Most Recent Events

04 Jun 2025 Amalgent therapeutics in collaboration with East Carolina University completes the Phase-I/II clinical trials in Pain in USA (IV) (NCT04160520)
30 May 2025 Preclinical trials in Pain in USA (IV) prior to October 2019 (Amalgent Therapeutics pipeline; May 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com